Literature DB >> 11096222

Immunological time-course of gadolinium-enhancing MRI lesions in patients with multiple sclerosis.

G Giovannoni1, N C Silver, C D Good, D H Miller, E J Thompson.   

Abstract

In multiple sclerosis (MS) gadolinium (Gd)-enhanced MRI activity correlates weakly with immunological markers of disease activity. We, therefore, tested the hypothesis that the poor correlation could be partly explained by the temporal profile of Gd enhancement. We measured urinary neopterin:creatinine ratios (neopt.:creat.(urine)) in 5 patients with active MS undergoing weekly Gd-enhanced MRI studies of the brain. The neopt.:creat.(urine) associated with new Gd-enhancing lesions (<8 days) was significantly higher than the ratio not associated with new Gd-enhancing lesions [mean(geometric) neopt.: creat.(urine) = 413 micromol/mol (range = 207-521) vs. 250 micromol/mol (range = 132-492), p = 0.03]. Pro-inflammatory immunological markers, which are probably produced early on in the life cycle of an active MS lesion, should preferably be correlated with newly enhancing lesions (<8 days). Failure to do this may explain the poor and unpredictable correlations between immunological markers and Gd-enhanced MRI activity, which cannot be accurately aged in cross-sectional and serial monthly MRI studies. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096222     DOI: 10.1159/000008241

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  3 in total

1.  Interpreting therapeutic effect in multiple sclerosis via MRI contrast enhancing lesions: now you see them, now you don't.

Authors:  Ilana R Leppert; S Narayanan; D Araújo; P S Giacomini; Y Lapierre; D L Arnold; G B Pike
Journal:  J Neurol       Date:  2014-02-26       Impact factor: 4.849

2.  Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis.

Authors:  John W Chen; Michael O Breckwoldt; Elena Aikawa; Gloria Chiang; Ralph Weissleder
Journal:  Brain       Date:  2008-01-29       Impact factor: 13.501

3.  Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS.

Authors:  Douglas L Arnold; Elizabeth Fisher; Vesna V Brinar; Jeffrey A Cohen; Alasdair J Coles; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Krzysztof W Selmaj; Miroslav Stojanovic; Howard L Weiner; Stephen L Lake; David H Margolin; David R Thomas; Michael A Panzara; D Alastair S Compston
Journal:  Neurology       Date:  2016-09-02       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.